Quick answers
- What is Benicar?
- Benicar is a brand name of Olmesartan medoxomil, a prescription medicine. The FDA NDC Directory lists 6 Benicar products in 3 strengths and forms.
- Who makes Benicar?
- Cosette holds the FDA application for Benicar (NDA021286, approved April 25, 2002).
- Is there a generic or store brand of Benicar?
- Yes. The FDA NDC Directory lists 70 other products with the same active ingredients, strength and form as a Benicar product, 70 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Benicar?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 3 Benicar strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Benicar been recalled?
- No recall linked to Benicar products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Benicar is
Each Benicar product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Olmesartan medoxomil · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| olmesartan medoxomil 20 mg tablet, film coated (oral) | Benicar | 25 products, 18 companies | DailyMed |
| olmesartan medoxomil 40 mg tablet, film coated (oral) | Benicar | 28 products, 18 companies | DailyMed |
| olmesartan medoxomil 5 mg tablet, film coated (oral) | Benicar | 17 products, 15 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Olmesartan medoxomil →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA021286 | Cosette | April 25, 2002 | 6 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| olmesartan medoxomil 20 mg tablet, film coated | Brand: Benicar | $12.32 per tablet Generic of the same strength and form: $0.0800 per tablet |
| olmesartan medoxomil 40 mg tablet, film coated | Brand: Benicar | $17.24 per tablet Generic of the same strength and form: $0.1113 per tablet |
| olmesartan medoxomil 5 mg tablet, film coated | Brand: Benicar | $10.13 per tablet Generic of the same strength and form: $0.0611 per tablet |
NADAC list of November 4, 2026; these prices took effect on July 1, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Benicar
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Benicar products.
- Cosette Pharmaceuticals, Inc.6 products
Recalls
No recall linked to Benicar products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.